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Abstract
Background: Brain metastases (BM) represent one of the most frequent complications related to
cancer, and their treatment continues to evolve. We have evaluated the activity, toxicity and the
impact on Quality of Life (QoL) of a concomitant treatment with whole brain radiotherapy
(WBRT) and Temozolomide (TMZ) in patients with brain metastases from solid tumors in a
prospective Simon two stage study.
Methods: Fifty-nine patients were enrolled and received 30 Gy WBRT with concomitant TMZ (75
mg/m2/day) for ten days, and subsequently TMZ (150 mg/m2/day) for up to six cycles. The primary
end points were clinical symptoms and radiologic response.
Results: Five patients had a complete response, 21 patients had a partial response, while 18
patients had stable disease. The overall response rate (45%) exceeded the target activity per study
design. The median time to progression was 9 months. Median overall survival was 13 months. The
most frequent toxicities included grade 3 neutropenia (15%) and anemia (13%), and only one
patient developed a grade 4 thrombocytopenia. Age, Karnofsky performance status, presence of
extracranial metastases and the recursive partitioning analysis (RPA) were found to be predictive
factors for response in patients. Overall survival (OS) and progression-free survival (PFS) were
dependent on age and on the RPA class.
Conclusion: We conclude that this treatment is well tolerated, with an encouraging objective
response rate, and a significant improvement in quality of life (p < 0.0001) demonstrated by FACT-
G analysis. All patients answered the questionnaires and described themselves as 'independent' and
able to act on their own initiatives. Our study found a high level of satisfaction for QoL, this
provides useful information to share with patients in discussions regarding chemotherapy
treatment of these lesions.
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Background
Brain metastases [BM] represent an important cause of
morbidity and mortality in cancer patients, and are the
most common intracranial tumor, occurring in approxi-
mately 10% to 30% of adult patients with cancer [1]. The
risk of developing brain metastasis varies according to pri-
mary tumor type. Approximately half of all brain metas-
tases occur due to lung cancer. More than 80% of brain
metastases are detected after the primary tumor has been
diagnosed; less frequently brain metastasis represent the
first manifestation of neoplasia and/or are diagnosed at
the same time as the primary tumor. The incidence of
these metastases has increased in recent years for several
reasons and they are associated with poor prognosis. The
median survival time of untreated patients is approxi-
mately 1 month [1]. Often these patients have severe neu-
rologic symptoms with a decrease in survival and quality
of life.
Treatment choices are limited: only patients with a single
brain metastasis benefit from surgery or radiosurgery. Fre-
quently the palliative approaches focused on sympto-
matic care remain the standard treatment to relieve
neurologic symptoms, primarily with the use of corticos-
teroids and anti-convulsant [2]. However, single metas-
tases are rare and whole brain radiotherapy remains the
standard treatment for most [3]. WBRT improves specific
neurologic symptoms in the majority of patients [4], but
response duration is short and the treatment may be asso-
ciated with late complications. Phase III trials of the Radi-
ation Therapy Oncology Group (RTOG) showed that
treatment of brain metastasis with WBRT results in a
median survival of 4 to 6 months and improves the neu-
rologic function in most patients. No difference in
median survival or 1-year survival has been seen between
various dose groups, including a comparison between
standard fractionation (30 Gy in 10 daily fractions) and
accelerated hyperfractionation (1.6 Gy twice daily to 54.4
Gy) [5].
Patients with brain metastases represent a heterogeneous
population. The Radiation Therapy Oncology Group clas-
sification derived from a recursive partitioning analysis
(RPA) identified three groups of patients according to
prognostic factors related to tumour based on Karnofsky
performance score, primary tumor status, presence of
extra-cranial metastases and age. Patients with KPS ≥70,
age < 65 years, no extra-cranial metastases and controlled
primary tumor are considered Class I and have a median
survival of 7.1 months; patients with KPS< 70 are class III
with a median survival of 2.3 months. All other patients
belong to class II with a median survival of 4.2 months
[6]. Most patients are in class II and III and the WBRT
remain standard treatment.
The role of systemic chemotherapy in the management of
BM is limited and controversial. The limited ability of
most chemotherapeutic agents to cross the blood-brain
barrier is believed to be one of the principal reasons these
agents are less active against disease in the central nervous
system than against extra-cranial, systemic disease [7].
Importantly, most patients have received most of the
standard chemotherapy agents by the time they develop
brain metastases and this increases tumor resistance. In
newly diagnosed brain metastases, the tumors are respon-
sive as the primary systemic cancer, as demonstrated by
several phase II studies. The response rates ranging from
50% with 80% in patients with primary breast and lung
cancer reported in some studies are associated to severe
adverse events [8]. Results of a few phase III studies com-
paring chemotherapy alone with combined chemother-
apy and WBRT do not allow firm conclusions [9], and
studies comparing chemotherapy alone to WBRT alone
are lacking. Nevertheless, it appears reasonable to con-
sider chemotherapy for brain metastases in specific situa-
tions, such as chemosensitive primary tumor, or systemic
metastases requiring chemotherapy. In fact, most patients
are in class II and III and WBRT remains standard treat-
ment.
Temozolomide (TMZ), an oral imidazotetrazinone meth-
ylating agent has demonstrated schedule-dependent activ-
ity in several cancers, including gliomas [10]. TMZ is
rapidly absorbed and is spontaneously cleaved in vivo to
monoethyl triazenoimidazole carboxamide (MTIC), a
reactive DNA methylating species. The cytotoxicity of
MTIC is thought to be caused by methylation of the O6
position of guanine [11]. TMZ is highly bio-available after
oral administration, has excellent central nervous system
penetration, and reaches the brain in therapeutic concen-
trations [12]. Myelosuppression is the primary toxicity
associated with TMZ, but it is non-cumulative, and man-
ageable in the majority of patients.
We have previously reported the results of a phase II study
demonstrating that the temozolomide/pegylated doxoru-
bicin regimen was well tolerated with encouraging activity
in brain metastases from solid tumors [13]. Previous stud-
ies have reported on the use of TMZ in the setting of recur-
rent or progressive brain metastasis with modest results
[14,15]. The concomitant use of TMZ and WBRT is well
tolerated and in a randomised phase II trial, showed a sig-
nificantly higher response rate in patients receiving TMZ
and radiotherapy versus radiotherapy alone [16,17], con-
firming the in vitro data on the combination of temozolo-
mide with radiation [18].
The primary aim of this study was to confirm the efficacy
and safety of the combination of TMZ and WBRT in
patients with previously untreated BM from solidBMC Cancer 2007, 7:18 http://www.biomedcentral.com/1471-2407/7/18
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tumours. The primary end points were conventional clin-
ical symptoms evaluation and neuro-imaging response
criteria. We also evaluated the impact of this treatment
combination on the quality of life of the patients enrolled
in the study, overall survival, progression free survival,
safety and tolerability.
Methods
Patient eligibility criteria
Adult patients with histologically proven primary cancer
with measurable brain metastases assessable by contrast-
enhanced computed tomography (CT) scan or gadolin-
ium-enhanced magnetic resonance imaging (MRI) that
were not suitable for surgery or radiosurgery, were eligible
for the study. Eligibility criteria included age ≥18 years;
KPS ≥50; a life expectancy of ≥3 months; serum creatinine
and total serum bilirubin ≤1.5 times the upper limit of
normal; adequate hematologic and hepatic function
(including absolute neutrophil count ≥1500/mm3, plate-
let count 100000/mm3, AST and ALT ≤3 times the upper
limit of normal). Patients who had received prior treat-
ment for brain metastases, or those with severe inter-cur-
rent medical illness or symptomatic heart disease, or
pregnant or lactating women, were ineligible. Eligible
patients were required to have fully recovered from previ-
ous therapy. The Institutional Ethics Committee approved
the protocol and patients were required to give informed
consent before beginning the treatment.
Study design
A two-stage Simon accrual design was adopted for this
phase II trial [19]. The minimum target activity level was
20% and early discontinuation of the study was planned
in case of no response in the first 12 assessable patients.
Alternatively, a planned sample size of 55 evaluable
patients was chosen to better estimate efficacy; with 25%
maximum width of the 95% confidence interval (CI) for
an expected 30% overall response rate. Time to progres-
sion (TTP) was measured from the date of registration to
the date of documented progressive disease or death.
Overall survival was measured from the time of registra-
tion to the date of death resulting from any cause. The pri-
mary endpoints were the analysis of tumor response and
feasibility. Secondary endpoints were the evaluation of
TTP, overall survival (OS), and median time to response.
TTP was measured from the date of registration to the date
of documented progressive disease or death. OS was
assessed from the time of registration to the date of death
resulting from any cause. TTP and OS were both deter-
mined by Kaplan-Meier product limit method [20]. The
median response duration was calculated from the date of
registration to the date of disease progression or death. All
analyses were performed following an intention to treat
approach.
Treatment schedule
Planned conventional WBRT was administrated with a
daily dose of 3 Gy × 5 days each week for two weeks to a
total dose of 30 Gy. TMZ was administrated orally at a
dosage of 75 mg/m2/day during the radiation treatment
and 150 mg/m2/day × 5 days every 28 days after RT to
fasting patients for a maximum of six additional cycles.
Treatment was continued until disease progression or
unacceptable toxicity. All patients received corticosteroids
at the lowest dose necessary to maintain neurologic stabil-
ity, and anti-convulsivants were given when indicated.
Blood counts were assessed weekly during therapy; liver,
renal function tests and electrolytes were monitored
before each cycle.
Patient evaluation
Baseline assessment were performed within 1 week before
the initiation of radiation treatment and included a com-
plete history and physical and neurologic examination,
evaluation of KPS, complete blood cell count, creatinine
clearance, liver enzymes, total bilirubin, and serum elec-
trolytes, total protein, albumin, and calcium. All patients
underwent weekly physical and neurologic examinations
during concurrent treatment and a complete clinical eval-
uation, laboratory tests, KPS and CT or MRI 30 days after
WBRT. Laboratory tests were done before each TMZ cycle.
Target lesions were assessed by computed tomography
(CT) or gadolinium-enhanced magnetic resonance imag-
ing (Gd-MRI) in the 2 weeks before the onset of treat-
ment, all scans were centrally reviewed by two blinded
radiologists. Radiologic evaluation of target lesions was
performed every time clinical evidence of neurologic pro-
gression was noted or every two 28-day cycles (within one
week before the day of dosing), and 4 weeks after the least
treatment cycle, according to the WHO/ECOG criteria
[21] as described below.
Complete response (CR): disappearance of all known
brain metastases. Partial response (PR): 50% or greater
decrease in measurable brain lesions or an objective
improvement in evaluable brain lesions. Stable disease
(SD): brain lesions unchanged (< 50% decrease or < 25%
increase in the size of measurable lesions). Progressive
disease (PD): >25% increase in size of some or all of brain
lesions and/or the appearance of any new brain lesions.
No CR, PR, or SD before increased disease or new lesions.
No brain lesion regresses.
All adverse events were recorded and graded according to
the CTC-NCI criteria (version 2.0).
Evaluation of QoL
Health-related QoL was measured using subject-com-
pleted Functional Assessment of Cancer Therapy (FACT)BMC Cancer 2007, 7:18 http://www.biomedcentral.com/1471-2407/7/18
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and FACT- brain metastases questionnaires developed for
use in clinical trials. The FACT-General (FACT-G) Version
4 is a 27-item core multidimensional questionnaire eval-
uating various domains of QL including physical, func-
tional, family, social, and emotional domains. Items are
summed to give scores for each domain, and an overall
QL score. The FACT-G questionnaire is available in 24 dif-
ferent languages and is widely accepted in the Italian lan-
guage [22]. The FACT-Br scale contains 53 questions with
high validity and good psychometric properties and effi-
cacy to assess QoL in patients with brain tumors [23]. We
selected only 26 of what there were considered the most
relevant questions. Patients responded to QoL questions
on a five-point Likert-type scale ranging from '0' ('not at
all') to '4' ('very much') [24].
The questionnaires were used to evaluate the QoL at base-
line, after 3 months, 6 months and 9 months.
Statistical analysis
A univariate analysis for each prognostic variable on over-
all survival and progression free survival was estimated
according to the Kaplan-Meier method [20]. The terminal
event was death attributable to any cause. The statistical
significance of the differences in survival distribution
among the prognostic groups was evaluated by the log-
rank test. Factors reaching significance of univariate anal-
ysis were entered in a multivariate analysis using the Cox
stepwise logistic regression test to investigate the inde-
pendence of the various risk factors.
P values <0.05 was regarded as statistically significant in
two tailed tests. The QoL data were analysed by ANOVA
test. SPSS software (version 10.00, SPSS, Chicago) was
used for statistical analysis.
Results
Patient characteristics
Between October 2001 and June 2004, 63 patients were
enrolled, and 59 patients completed RT and were assessa-
ble for efficacy and safety. Four patients refused treatment.
The demographics and baseline disease characteristics of
the assessable patients are listed in Table 1.
Among 59 assessable patients 22 (37%) had non-small-
cell lung cancer, 16 (28%) had other cancer (colo-rectal
carcinomas, melanoma, ovarian cancer and testicular can-
cer), and 21 (35%) had breast cancer; 33 (56%) of 59
patients had metastases in other organs. The majority of
patients, 34 out 59, had received chemotherapy for pri-
mary cancer before entering the study. According to RPA
analysis, class I included 21 patients, the class II 22, class
III 16 patients.
Response of Brain Lesions to Treatment
Fifty-nine patients were assessable for response. Five CRs,
in patients with breast cancer and NSCLC, and 21 PRs
were recorded in 12/21 patients with breast cancer, 8/22
patients with NSCLC and 1 in other cancers, while a stable
disease was achieved in other 19 patients. All the
responses have been defined on the basis of measurable
Table 1: Patients characteristics
Characteristics No. of patients
Age (y)
≥65 27
<65 32
Gender
Male 27
Female 32
KPS
≥70 40
<70 19
Primary tumour
Lung 22
Breast 21
Other 16
Extracranial metastasis
Yes 33
No 26
RPA Class
I 21
II 22
II 16
Previous chemotherapy
Yes 34
No 25BMC Cancer 2007, 7:18 http://www.biomedcentral.com/1471-2407/7/18
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brain lesions. As shown in Table 2, the overall response
rate was 44% (C.I. 38.3–56.6%), while the disease control
rate was 76.3% (C.I. 61.2–81.9%). The median progres-
sion free survival was 9.00 months (95% CI: 7.93 –
10.07). Patients treated with WBRT and TMZ had a slight
improvement in OS: 13.00 months (95% C.I.: 11.89 –
14.11) compared to data in the literature for WBRT alone
(Fig. 1).
The statistical analysis of factors predictive for response
revealed that the BM disease control, after WBRT/TMZ
treatment, depended on age ≤ 65 years (p < 0.0001),
Karnofsky Performance Status ≥ 70 (p < 0.0001), no extra-
cranial disease (p = 0,012), RPA class I (p < 0.0001) (Table
3).
Univariate analysis for PFS showed statistically significant
differences for the presence of extra-cranial disease (p =
0.02), age < 65 years, KPS ≥ 70 and RPA class I (Table 4).
Factors predictive for improved overall survival, in univar-
iate analysis, included KPS ≥ 70, age ≤ 65 years and lower
RPA class (Table 4).
To confirm these results we performed a multivariate
analysis: the patients with KPS ≥70 (p < 0.05) and those
included in the first RPA class (p = 0.001), respectively,
showed a statistically significant improvements of the
time to progression (Table 5). The multivariate analysis
for OS confirmed the central role for KPS ≥70 (p = 0.024)
and the first RPA class (p = 0.004) in predicting OS (Table
5). The multivariate analysis performed excluding RPA
confirmed the role of all radiological response, age and
age in predicting both OS and PFS (Table 6).
Safety and Tolerability
Acute side-effects are summarized in Table 7. The addition
of TMZ to RT was generally well tolerated. The most com-
mon toxicities were neutropenia (35%) and anemia
(22%). Grade III neutropenia developed in 9 patients
(15%). The most frequent non hematologic events were ≥
grade 2 occurring in about 5% of patients including nau-
sea, vomiting, headache, fatigue and rash. Most side
effects were grade 2 and were well controlled by support-
ive care. Hepatic, renal, cardiac or severe neurological tox-
icity were not observed in our series. One patient required
dose reduction of TMZ (125 mg/m2/day) as a result of
grade IV thrombocytopenia, and four patients had a dose
delay because of TMZ-associated persistent neutropenia.
The WBRT/TMZ combined treatment was overall well tol-
erated in almost all patients.
Impact of WBRT/TMZ on quality of life
All patients who answered the questionnaire at baseline
were included in the evaluation, and the FACT-G score
was compared with the baseline value for each of these
patients. Baseline questionnaires were completed by 59
patients (100%). The rate of completed questionnaires
decreased as follows: first evaluation, after 3 months,
93%, second evaluation, after 6 months, 62 %, and third
evaluation, after nine months, 57%. As shown in Fig. 2,
we found a statistically significant improvement meas-
ured by the questionnaire. These results evidence an inter-
esting positive impact of this therapy in patients with
brain metastases after 3 and 6 months from the beginning
of the treatment with TMZ. These data suggest that TMZ
has superior palliative effects despite the presence of tox-
The Overall survival has been constructed by the Kaplan- Meier method Figure 1
The Overall survival has been constructed by the Kaplan-
Meier method. The median OS was 13.00 months (95% C.I.: 
11.89 – 14.11).
Table 2: Brain Lesion Response to Treatment
TMZ/WBRT
Parameter No. pts %
Complete Response [CR] 5 8.5
Partial Response [PR] 21 35.5
Objective Response [CR+PR] 26 44
Stable Disease 19 32.3
Progressive Disease 14 23.7BMC Cancer 2007, 7:18 http://www.biomedcentral.com/1471-2407/7/18
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icity. Overall, the aspects of the quality of life that are
assessed with the FACT-G questionnaire were maintained
or improved during treatment, with the greatest benefit
occurring for BM-specific concerns. The FACT-Br ques-
tionnaire confirmed these encouraging results as we
found an amelioration of quality of their life after three
months. From the FACT-Br survey, 26 questions were
asked and the mean and median scores for each question
from all the respondents were tabulated. The analysis of
the respondents, 34 patients, reported that they were
'quite a bit' or 'very much' content with the quality of their
life after 3 months of treatment (79% positive respond-
ents to 21% negative respondent), on the other and, the
baseline value were following: positive respondents 51%,
21 patients, and negative respondents 49% (those
patients who responded "not at all"/"a little bit"), 20
patients. The completion rates for the FACT-Br scores at 6
(38%) and 9 (30%) months were too low to provide a
meaningful comparison.
Discussion and Conclusion
The clinical studies evaluating the role of chemotherapy
in BM have been mostly non randomised Phase II trials.
The results have been often divergent due to variability in
several factors, including tumor histology, presenting
stage, previous use of chemotherapy, etc. [25]. Two rand-
omized phase III studies have confirmed the efficacy of
chemotherapy in BM. One, of concurrent chemotherapy
plus radiotherapy in BM from non-small-cell lung cancer
[26], suggested that the timing of WBRT, with respect to
chemotherapy with cisplatin and vinorelbine did not
influence survival. The other, evaluating effect of adding
WBRT to teniposide in small cell lung cancer, resulted in
a better response rate and longer time to BM progression
but had no impact on survival [27]. Several trials of TMZ
plus radiation therapy have been conducted in patients
with newly diagnosed brain metastases. Previous studies
demonstrated that TMZ treatment is safe and well-toler-
ated when combined with RT but no significant improve-
ments in survival was noted, compared to WBRT alone.
Improvement in neurologic functional status has been
reported with the combination, but there are no signifi-
cant data about the influence on overall responses and
QoL. In fact, the efficacy and safety of temozolamide con-
currently with WBRT for patients with newly diagnosed
brain metastases was evaluated in recent trials. The largest
of these trials demonstrated a significant improvement of
response rate and trend toward improved survival in the
arm of combined therapy (8.3 vs. 6.3 months; p = 0.179)
that was however not statistically significant [7]. Our data,
revealing a 44% overall response rate (CR+PR) with 8,5%
CR rate and the 76% brain disease control rate, appear
encouraging. Patients treated with WBRT and TMZ had a
slight improvement in OS as compared to the study of
Antonadou et al. that yielded a median OS time of 8.6
months in the arm of concomitant treatment with WBRT
and temozolamide [16]. More recently, a phase II trial of
temozolomide and cisplatin followed by whole brain
radiotherapy in NSCLC patients with brain metastases
demonstrated a median OS of 5 months [28].
Table 3: Analysis of clinical predictive factors.
Clinical predictive factors for response
Tumor control (SD, CR, PR) Brain progression (PD) P value
Lung Cancer 16 7 0.363
All the others 29 7
Males 25 7 0.321
Females 17 10
KPS <70 6 10 < 0.0001
KPS ≥70 29 4
No previous chemotherapy 20 5 0.758
Previous chemotherapy 25 9
No extracranial disease 25 2 0.012
Extracranial disease 20 12
Age > 65 years 6 10 <0.0001
Age ≤65 years 39 4
RPA as a predictive factor for response
Tumor control (SD, CR, PR) Brain progression (PD) P value
RPA 1 14 0 < 0.0001
RPA 2 25 4
RPA 3 6 10BMC Cancer 2007, 7:18 http://www.biomedcentral.com/1471-2407/7/18
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Table 4: Statistical analysis for OS and PFS.
Univariate Analysis for Overall Survival (OS) cancer patients with brain metastases
OS (months) 95% C.I. P value
Radiological response:
Tumor control (SD, CR, PR) 13.00 12.35 – 13.65 < 0.0001
Brain progression (PD) 5.00 3.83 – 6.17
Lung Cancer 13.00 12.10 – 13.90 0.9263
All the others 12.00 10.32 – 13.68
Males 11.00 7.63 – 14.37 0.239
Females 13.00 12.22 – 13.78
KPS <70 5.00 2.39 – 7.61 0.0006
KPS ≥ 70 13.00 12.37 – 13.63
No previous chemotherapy 13.00 11.53 – 14.47 0.7568
Previous chemotherapy 12.00 10.86 – 13.14
No extracranial disease 13.00 13.19 – 14.81 0.0681
Extracranial disease 10.00 7.31 – 14.69
Age > 65 years 6.00 2.56 – 9.23 0.0050
Age ≤ 65 years 12.00 10.01 – 13.67
RPA 1 13.00 11.95 – 14.05 0.0025
RPA 2 13.00 12.16 – 13.84
RPA 3 5.00 2.39 – 7.61
Univariate Analysis for Progression Free Survival (PFS) cancer patients with brain metastases
PFS (months) 95% C.I. P value
Radiological response:
Tumor control (SD, CR, PR) 10.00 8.54 – 11.46 < 0.0001
Brain progression (PD) 4.00 3.63 – 4.37
Lung Cancer 9.00 7.85 – 10.15 0.3578
All the others 10.00 7.67 – 12,33
Males 9.00 7.42 – 10.58 0.4815
Females 9.00 6.50 – 11.50
KPS <70 4.00 3.22 – 4.78 0.0016
KPS ≥ 70 10.00 8.40 – 11.60
No previous chemotherapy 10.00 8.05 – 11.95 0.7835
Previous chemotherapy 8.00 6.73 – 9.27
No extracranial disease 11.00 9.54 – 12.45 0.0247
Extracranial disease 8.00 5.80 – 10.20
Age > 65 years 5.00 4.10 – 6.43 0.02
Age ≤ 65 years 10.00 7.22 – 11.98
RPA 1 11.00 8.56 – 13.44 0.0027
RPA 2 9.00 7.25 – 10.75
RPA 3 4.00 3.22 – 4.78BMC Cancer 2007, 7:18 http://www.biomedcentral.com/1471-2407/7/18
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The responses were independent from the type of the pri-
mary tumor, gender and previous chemotherapy. In
details, also the inclusion of brain metastases from breast
cancer in the analysis did not change these results (data
not shown). Furthermore, in our series KPS <70, age >65
years, presence of other extra-cranial metastases and RPA
class III represent unfavourable factors for response. We
have also demonstrated that KPS and age influence PFS
and OS.
The results of this study suggest that the combination of
WBRT and TMZ has a significant clinical activity in
patients with brain metastases from solid tumours. The
overall objective response plus stabilization rate of 78,9%
is similar to that typically achieved with WBRT alone (61–
91%). However, the responses achieved in this study were
also reasonably durable with a median progression free
survival of 9 months. Moreover, the median survival of 13
months is good for such an advanced-staged patient pop-
ulation. These results appear better than others obtained
in previous trials; a possible explanation is the presence in
our series of a high number of patients in the I and II RPA
class.
This regimen was generally well tolerated by almost all
patients, including elderly patients (>70 years) (12/59).
The addition of daily TMZ to WBRT resulted in only one
grade 4 hematologic toxicity. When neutropenia or
thrombocytopenia developed, it resolved quickly and
resulted in only minor treatment delays up to one week,
with only one patient requiring dose reduction to 125 mg/
m2 of TMZ. In our series of patients we observed a consid-
erable improvement in QoL, measured using the FACT-G
and FACT-Br questionnaires. These data confirm previous
results which showed an amelioration of QoL also in
patients who did not obtain an objective response.
The results of our QoL analysis shows a high level of sat-
isfaction among patients who have undergone TMZ plus
WBRT treatment for brain metastases and provides excel-
lent support for its acceptability. The benefits of treat-
ment-related efficacy were not affected by symptoms
caused by the toxic effect. The results of the present study
support the efficacy and safety of WBRT and TMZ in the
treatment of patients with BM from a variety of solid
tumors and confirm that this combination can also offer
significant palliation for BM, improving global QoL.
Though the presented data looks promising, this will need
to be further validated within the settings of a randomized
trial.
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Table 5: Multivariate analysis for OS and PFS.
Overall Survival (OS) P value
Tumour control (SD, CR, PR) 0.007
Brain progression (PD)
KPS <70 0.024
KPS ≥ 70
Age ≤ 65 years 0.792
Age > 65 years
RPA 1 0.004
RPA 2
RPA 3
Progression Free Survival (PFS) P value
Tumor control (SD, CR, PR) 0.001
Brain progression (PD)
KPS <70 0.05
KPS ≥ 70
No extracranial disease 0.810
Extracranial disease
Age > 65 years 0.310
Age ≤ 65 years
RPA 1 0.001
RPA 2
RPA 3BMC Cancer 2007, 7:18 http://www.biomedcentral.com/1471-2407/7/18
Page 9 of 11
(page number not for citation purposes)
Authors' contributions
RA and SDP projected the study and participated in its
design and coordination;
RA and MC participated in drafting the manuscript.
RG, VF, LC and LM carried out all the treatment and the
patients' follow-up.
LM, RA and SDP participated in acquisition of data and
gave substantive intellectual contribution when revising it
critically;
BV and EC performed the analysis of the data.
All authors read and approved the final manuscript.
Table 7: Most common and serious Adverse events During TMZ/WBRT treatment according to Common Toxicity Criteria extended 
by National Cancer Institute, (NCI CTC) in the 59 enrolled patients.
Grade 2 Grade 3 Grade 4
Toxicity No. pts % No. pts % No. pts %
Neutropenia 15 25 9 15 - -
Thrombocytopeni
a
472311
A n e m i a 71 281 3- -
A l o p e c i a 23----
V o m i t i n g 61 02 3
hand and foot 
syndrome
23----
H e a d a c h e5811--
N a u s e a 5823--
T r e m o r 4723--
N e r o s e n s o r y 35----
Fatigue 7 12 2 3 - -
R a s h 81 33 5 - -
Table 6: Multivariate analysis for OS and PFS without RPA.
Overall Survival (OS) P value
Tumour control (SD, CR, PR) <0.0001
Brain progression (PD)
KPS ≤60 0.002
KPS >60
Age ≤65 years 0.01
Age >65 years
Progression Free Survival (PFS) P value
Tumor control (SD, CR, PR) <0.0001
Brain progression (PD)
KPS ≤60 0.003
KPS >60
No extracranial disease 0.325
Extracranial disease
Age >65 years 0.01
Age ≤65 yearsBMC Cancer 2007, 7:18 http://www.biomedcentral.com/1471-2407/7/18
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Variations (mean ± SD) in QoL in TMZ/WBRT treated pts. 
Statistical analysis has been performed by ANOVA compar-
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